Pyxis Oncology, Inc.
PYXSNasdaq
$2.36
↑ +5.8%Jul 17 close · end-of-day
Price
1Y↑ +98.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$149.8M
Enterprise Value
$108.8M
P/E
—
P/S
—
P/B
4.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$81.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-261.4%
ROIC
—
Debt / Equity
—
Net Cash
$41.0M
Return 1Y
+101.7%
Company profile
Pyxis Oncology, Inc. engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
- CEO
- Lara S. Sullivan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- pyxisoncology.com
Earnings
PYXS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.37↑ +5.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $16.1M | $13.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.9M | -$69.7M | -$123.5M | -$82.2M | -$89.5M | -$84.4M |
| Net income | -$12.8M | -$76.0M | -$120.7M | -$73.8M | -$77.3M | -$79.6M |
| Diluted EPS | — | -$8.95 | -$3.65 | -$1.85 | -$1.32 | -$1.28 |
| Operating cash flow | -$10.1M | -$35.3M | -$89.3M | -$70.7M | -$57.7M | -$63.5M |
| Free cash flow | -$11.6M | -$35.9M | -$95.7M | -$77.4M | -$57.9M | -$63.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -554.1% | -609.2% |
| Net margin | — | — | — | — | -478.9% | -574.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | $2.8M | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$20.0M | -$23.8M | -$40.1M | -$22.9M | -$19.8M | -$23.5M | -$18.3M | -$24.4M |
| Net income | -$17.3M | -$21.2M | -$35.6M | -$21.2M | -$18.4M | -$22.0M | -$18.1M | -$23.3M |
| Diluted EPS | -$0.29 | -$0.35 | -$0.62 | -$0.35 | -$0.30 | -$0.35 | -$0.28 | -$0.37 |
| Operating cash flow | -$3.0M | -$14.7M | -$19.3M | -$22.5M | -$17.3M | -$13.3M | -$10.4M | -$26.0M |
| Free cash flow | -$3.0M | -$14.7M | -$19.3M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -700.4% | — | — | — |
| Net margin | — | — | — | — | -650.9% | — | — | — |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Dupont Jakob | Sale | 35,000 | $3.06 | $107,100.00 | filing |
| 2026-06-30 | Dupont Jakob | Option exercise | 35,000 | $1.60 | $56,000.00 | filing |
| 2026-03-24 | Wadhane Jitendra· Prin Fin & Acct Officer | Award | 109,461 | $0.00 | $0.00 | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.